Antiamyloidogenic and Neuroprotective Functions of Cathepsin B: Implications for Alzheimer's Disease

Neuron

Volumn 51, Issue 6, 2006, Pages 703-714

  Mueller Steiner, Sarah ^a,b   Zhou, Yungui ^a   Arai, Hideaki ^a,c   Roberson, Erik D ^a,b   Sun, Binggui ^a,b   Chen, Jennifer ^a,b   Wang, Xin ^a   Yu, Guiqiu ^a   Esposito, Luke ^a,b   Mucke, Lennart ^a,b   Gan, Li ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

HUMDISEASE; MOLNEURO

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CATHEPSIN B; CYSTEINE PROTEINASE; LENTIVIRUS VECTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; THIOFLAVINE;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE INACTIVATION; GENE TRANSFER; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; WESTERN BLOTTING;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CATHEPSIN B; CELL LINE, TUMOR; FEMALE; HUMANS; HYDROLYSIS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON; MUTATION; NEURITES; NEURONS; PEPTIDE FRAGMENTS; SENILE PLAQUES;

EID: 33748524564     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2006.07.027     Document Type: Article

References (66)

1. Authier F., Metioui M., Bell A.W., and Mort J.S. Negative regulation of epidermal growth factor signaling by selective proteolytic mechanisms in the endosome mediated by cathepsin B. J. Biol. Chem. 274 (1999) 33723-33731
2. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82 (1991) 239-259
3. Buck M.R., Karustis D.G., Day N.A., Honn K.V., and Sloane B.F. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem. J. 282 (1992) 273-278
4. Cataldo A.M., and Nixon R.A. Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc. Natl. Acad. Sci. USA 87 (1990) 3861-3865
5. Cataldo A.M., Barnett J.L., Pieroni C., and Nixon R.A. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: Neuropathologic evidence for a mechanism of increased β-amyloidogenesis. J. Neurosci. 17 (1997) 6142-6151
6. Cataldo A.M., Petanceska S., Terio N.B., Peterhoff C.M., Durham R., Mercken M., Mehta P.D., Buxbaum J., Haroutunian V., and Nixon R.A. Aβ localization in abnormal endosomes: Association with earliest Aβ elevations in AD and Down syndrome. Neurobiol. Aging 25 (2004) 1263-1272
7. Chapman H.A., Riese R.J., and Shi G.P. Emerging roles for cysteine proteases in human biology. Annu. Rev. Physiol. 59 (1997) 63-88
8. Chen J., Zhou Y., Mueller-Steiner S., Chen L.F., Kwon H., Yi S., Mucke L., and Gan L. SIRT1 protects against microglia-dependent amyloid-β toxicity through inhibiting NF-κB signaling. J. Biol. Chem. 280 (2005) 40364-40374
9. Cheng I.H., Palop J.J., Esposito L.A., Bien-Ly N., Yan F., and Mucke L. Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat. Med. 10 (2004) 1190-1192
10. Chin J., Palop J.J., Puolivali J., Massaro C., Bien-Ly N., Gerstein H., Scearce-Levie K., Masliah E., and Mucke L. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 25 (2005) 9694-9703
11. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., and Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8 (2005) 79-84
12. Comings D.E., and MacMurray J.P. Molecular heterosis: a review. Mol. Genet. Metab. 71 (2000) 19-31
13. Dahlgren K.N., Manelli A.M., Stine Jr. W.B., Baker L.K., Krafft G.A., and LaDu M.J. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem. 277 (2002) 32046-32053
14. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98 (2001) 8850-8855
15. Deussing J., Roth W., Saftig P., Peters C., Ploegh H.L., and Villadangos J.A. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc. Natl. Acad. Sci. USA 95 (1998) 4516-4521
16. Eckman E.A., Reed D.K., and Eckman C.B. Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J. Biol. Chem. 276 (2001) 24540-24548
17. Esposito L., Gan L., Yu G.Q., Essrich C., and Mucke L. Intracellularly generated amyloid-beta peptide counteracts the antiapoptotic function of its precursor protein and primes proapoptotic pathways for activation by other insults in neuroblastoma cells. J. Neurochem. 91 (2004) 1260-1274
18. Frautschy S.A., Horn D.L., Sigel J.J., Harris-White M.E., Mendoza J.J., Yang F., Saido T.C., and Cole G.M. Protease inhibitor coinfusion with amyloid β-protein results in enhanced deposition and toxicity in rat brain. J. Neurosci. 18 (1998) 8311-8321
19. Gan L., Ye S., Chu A., Anton K.E., Yi S., Vincent V.A., von Schack D., Chin D., Murray J., Lohr S., et al. Identification of cathepsin B as a mediator of neuronal death induced by Aβ-activated microglial cells using a functional genomics approach. J. Biol. Chem. 279 (2004) 5565-5572
20. Glenner G.G., and Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120 (1984) 885-890
21. Gouras G.K., Xu H., Jovanovic J.N., Buxbaum J.D., Wang R., Greengard P., Relkin N.R., and Gandy S. Generation and regulation of β-amyloid peptide variants by neurons. J. Neurochem. 71 (1998) 1920-1925
22. Hamilton Jr. R.L., Goerke J., Guo L.S., Williams M.C., and Havel R.J. Unilamellar liposomes made with the French pressure cell: a simple preparative and semiquantitative technique. J. Lipid Res. 21 (1980) 981-992
23. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297 (2002) 353-356
24. Hartley D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., Teplow D.B., and Selkoe D.J. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19 (1999) 8876-8884
25. Hashimoto Y., Kakegawa H., Narita Y., Hachiya Y., Hayakawa T., Kos J., Turk V., and Katunuma N. Significance of cathepsin B accumulation in synovial fluid of rheumatoid arthritis. Biochem. Biophys. Res. Commun. 283 (2001) 334-339
26. Hook V.Y., Toneff T., Aaron W., Yasothornsrikul S., Bundey R., and Reisine T. β-amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for β-secretase activity in chromaffin vesicles. J. Neurochem. 81 (2002) 237-256
27. Hook V., Toneff T., Bogyo M., Greenbaum D., Medzihradszky K.F., Neveu J., Lane W., Hook G., and Reisine T. Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease. Biol. Chem. 386 (2005) 931-940
28. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A., and Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA 96 (1999) 3228-3233
29. Huang S.M., Mouri A., Kokubo H., Nakajima R., Suemoto T., Higuchi M., Staufenbiel M., Noda Y., Yamaguchi H., Nabeshima T., et al. Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J. Biol. Chem. 281 (2006) 17941-17951
30. Iijima K., Liu H.P., Chiang A.S., Hearn S.A., Konsolaki M., and Zhong Y. Dissecting the pathological effects of human Aβ40 and Aβ42 in Drosophila: A potential model for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 101 (2004) 6623-6628
31. Illy C., Quraishi O., Wang J., Purisima E., Vernet T., and Mort J.S. Role of the occluding loop in cathepsin B activity. J. Biol. Chem. 272 (1997) 1197-1202
32. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N.P., Gerard C., Hama E., Lee H.-J., and Saido T.C. Metabolic regulation of brain Aβ by neprilysin. Science 292 (2001) 1550-1552
33. Iwata N., Mizukami H., Shirotani K., Takaki Y., Muramatsu S., Lu B., Gerard N.P., Gerard C., Ozawa K., and Saido T.C. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J. Neurosci. 24 (2004) 991-998
34. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D., et al. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA 94 (1997) 1550-1555
35. 3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 20 (2000) 4106-4114
36. Kanemitsu H., Tomiyama T., and Mori H. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci. Lett. 350 (2003) 113-116
37. Khouri H.E., Plouffe C., Hasnain S., Hirama T., Storer A.C., and Menard R. A model to explain the pH-dependent specificity of cathepsin B-catalysed hydrolyses. Biochem. J. 275 (1991) 751-757
38. Koistinaho M., Lin S., Wu X., Esterman M., Koger D., Hanson J., Higgs R., Liu F., Malkani S., Bales K.R., and Paul S.M. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides. Nat. Med. 10 (2004) 719-726
39. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95 (1998) 6448-6453
40. Lazarov O., Robinson J., Tang Y.P., Hairston I.S., Korade-Mirnics Z., Lee V.M., Hersh L.B., Sapolsky R.M., Mirnics K., and Sisodia S.S. Environmental enrichment reduces Aβ levels and amyloid deposition in transgenic mice. Cell 120 (2005) 701-713
41. Leissring M.A., Farris W., Chang A.Y., Walsh D.M., Wu X., Sun X., Frosch M.P., and Selkoe D.J. Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40 (2003) 1087-1093
42. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., and Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
43. Linebaugh B.E., Sameni M., Day N.A., Sloane B.F., and Keppler D. Exocytosis of active cathepsin B. Enzyme activity at pH 7.0, inhibition and molecular mass. Eur. J. Biochem. 264 (1999) 100-109
44. Mackay E.A., Ehrhard A., Moniatte M., Guenet C., Tardif C., Tarnus C., Sorokine O., Heintzelmann B., Nay C., Remy J.M., et al. A possible role for cathepsins D, E, and B in the processing of b-amyloid precursor protein in Alzheimer's disease. Eur. J. Biochem. 244 (1997) 414-425
45. Marr R.A., Rockenstein E., Mukherjee A., Kindy M.S., Hersh L.B., Gage F.H., Verma I.M., and Masliah E. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J. Neurosci. 23 (2003) 1992-1996
46. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., and Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 82 (1985) 4245-4249
47. 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J. Neurosci. 20 (2000) 4050-4058
48. Musil D., Zucic D., Turk D., Engh R.A., Mayr I., Huber R., Popovic T., Turk V., Towatari T., Katunuma N., et al. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: The structural basis for its specificity. EMBO J. 10 (1991) 2321-2330
49. Nagler D.K., Storer A.C., Portaro F.C., Carmona E., Juliano L., and Menard R. Major increase in endopeptidase activity of human cathepsin B upon removal of occluding loop contacts. Biochemistry 36 (1997) 12608-12615
50. Oddo S., Caccamo A., Smith I.F., Green K.N., and LaFerla F.M. A dynamic relationship between intracellular and extracellular pools of Aβ. Am. J. Pathol. 168 (2006) 184-194
51. Palop J.J., Jones B., Kekonius L., Chin J., Yu G.-Q., Raber J., Masliah E., and Mucke L. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. USA 100 (2003) 9572-9577
52. Palop J.J., Chin J., Bien-Ly N., Massaro C., Yeung B.Z., Yu G.Q., and Mucke L. Vulnerability of dentate granule cells to disruption of arc expression in human amyloid precursor protein transgenic mice. J. Neurosci. 25 (2005) 9686-9693
53. Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., and Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J. Biol. Chem. 273 (1998) 32730-32738
54. Saito T., Iwata N., Tsubuki S., Takaki Y., Takano J., Huang S.M., Suemoto T., Higuchi M., and Saido T.C. Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation. Nat. Med. 11 (2005) 434-439
55. Selkoe D.J. Clearing the brain's amyloid cobwebs. Neuron 32 (2001) 177-180
56. Takahashi R.H., Almeida C.G., Kearney P.F., Yu F., Lin M.T., Milner T.A., and Gouras G.K. Oligomerization of Alzheimer's β-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24 (2004) 3592-3599
57. Tanzi R.E., and Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120 (2005) 545-555
58. Tsujinaka T., Ebisui C., Fujita J., Morimoto T., Ogawa A., Ishidoh K., Kominami E., Yano M., Shiozaki H., and Monden M. Autocatalytic inactivation of lysosomal cathepsins is associated with inhibition of protein breakdown by insulin-like growth factor-1 (IGF-1) in myotubes. Biochem. Biophys. Res. Commun. 208 (1995) 353-359
59. Tucker H.M., Kihiko M., Caldwell J.N., Wright S., Kawarabayashi T., Price D., Walker D., Scheff S., McGillis J.P., Rydel R.E., and Estus S. The plasmin system is induced by and degrades amyloid-beta aggregates. J. Neurosci. 20 (2000) 3937-3946
60. Vekrellis K., Ye Z., Qiu W.Q., Walsh D., Hartley D., Chesneau V., Rosner M.R., and Selkoe D.J. Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20 (2000) 1657-1665
61. Walsh D.M., and Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44 (2004) 181-193
62. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
63. Wyss-Coray T., Lin C., Yan F., Yu G.Q., Rohde M., McConlogue L., Masliah E., and Mucke L. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nat. Med. 7 (2001) 612-618
64. Yamin R., Malgeri E.G., Sloane J.A., McGraw W.T., and Abraham C.R. Metalloendopeptidase EC 3.4.24.15 is necessary for Alzheimer's amyloid-beta peptide degradation. J. Biol. Chem. 274 (1999) 18777-18784
65. Yan P., Hu X., Song H., Yin K., Bateman R.J., Cirrito J.R., Xiao Q., Hsu F.F., Turk J.W., Xu J., et al. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J. Biol. Chem. 281 (2006) 24566-24574
66. Zhang Y., McLaughlin R., Goodyer C., and LeBlanc A. Selective cytotoxicity of intracellular amyloid β peptide1-42 through p53 and Bax in cultured primary human neurons. J. Cell Biol. 156 (2002) 519-529